Commercially available prognostic molecular models in early-stage lung cancer: A review of the Pervenio Lung RS and Myriad myPlan Lung Cancer tests

Expert Review of Molecular Diagnostics

Volumn 15, Issue 5, 2015, Pages 589-596

  Zheng, Yifan ^a   Bueno, Raphael ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

gene expression profile; lung cancer prognostic test; myPlan Lung Cancer; Pervenio Lung RS; prognostic model

Indexed keywords

MOLECULAR MARKER; DIAGNOSTIC KIT; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; DIAGNOSTIC TEST; EARLY CANCER; GENE EXPRESSION; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; MOLECULAR MODEL; REVIEW; RISK ASSESSMENT; CANCER STAGING; DIAGNOSTIC KIT; ECONOMICS; GENETICS; LUNG NEOPLASMS; MOLECULAR DIAGNOSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; STANDARDS;

BIOMARKERS, TUMOR; HUMANS; LUNG NEOPLASMS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASM STAGING; PROGNOSIS; REAGENT KITS, DIAGNOSTIC;

EID: 84928381260     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.2015.1028371     Document Type: Review

References (41)

1. World Health Organization. Cancer. Media Centre. 2014. Available from: www.who.int/ mediacentre/factsheets/fs297/en/ [Last accessed 04 March 2015]
2. American Cancer Society. What are the key statistics about lung cancer? 2014. Available from: www.cancer.org/cancer/lungcancernon- smallcell/detailedguide/non-small-celllung- cancer-key-statistics [Last accessed 03 April 2015]
3. American Cancer Society. Non-small cell lung cancer survival rates by stage. 2014. Available from: www.cancer.org/cancer/ lungcancer-non-smallcell/detailedguide/nonsmall- cell-lung-cancer-survival-rates [Last accessed 03 April 2015]
4. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2(8):706-14
5. Chansky K, Sculier JP, Crowley JJ, et al. The international association for the study of lung cancer staging project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009;4(7):792-801
6. Douillard JY, Tribodet H, Aubert D, et al. Adjuvant cisplatin and vinorelbine for completely resected non-small cell lung cancer: subgroup analysis of the lung adjuvant cisplatin evaluation. J Thorac Oncol 2010;5(2):220-8
7. Crinò L, Weder W, van Meerbeeck J, et al. Early stage and locally advanced (nonmetastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v103-15
8. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and leukemia group B, radiation therapy oncology group, and north central cancer treatment group study groups. J Clin Oncol 2008;26(31):5043-51
9. Graziano SL, Gu L, Wang X, et al. Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. J Thorac Oncol 2010; 5(6):810-17
10. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26(21):3552-9
11. Vilmar AC, Santoni-Rugiu E, Sørensen JB. ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. Ann Oncol 2010;21(9):1817-24
12. Li XQ, Li J, Shi SB, et al. Expression of MRP1, BCRP, LRP and ERCC1 as prognostic factors in non-small cell lung cancer patients receiving postoperative cisplatin-based chemotherapy. Int J Biol Markers 2009;24(4):230-7
13. Subramanian J, Simon R. Gene expression- based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010;102(7):464-74
14. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 2001;98(24): 13790-5
15. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res 2002;62(11):3005-8
16. Gordon GJ, Richards WG, Sugarbaker DJ, et al. A prognostic test for adenocarcinoma of the lung from gene expression profiling data. Cancer Epidemiol Biomarkers Prev 2003;12(9):905-10
17. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8(8):816-24
18. Lu Y, Lemon W, Liu PY, et al. A gene expression signature predicts survival of patients with stage I non-small cell lung cancer. Public Libr Sci Med 2006;3(12): e467
19. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25(35):5562-9
20. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma. Shedden K, Taylor JM, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14(8):822-7
21. Roepman P, Jassem J, Smit EF, et al. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Clin Cancer Res 2009;15(1):284-90
22. Boutros PC, Lau SK, Pintilie M, et al. Prognostic gene signatures for non-small-cell lung cancer. Proc Natl Acad Sci USA 2009; 106(8):2824-8
23. Collisson EA, Campbell JD, Brooks AN, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511(7511):543-50
24. Hammerman PS, Lawrence MS, Voet D, et al. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489(7417):519-25
25. Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012;379(9818):823-32
26. Raz DJ, Ray MR, Kim JY, et al. A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res 2008; 14(17):5565-70
27. Kratz JR, Van den Eeden SK, He J, et al. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. J Am Med Assoc 2012;308(16):1629-31
28. Kratz JR, Tham PT, Mulvihill MS, et al. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer. Diagn Mol Pathol 2013;22(2):65-9
29. National Human Genome Research Institute. Reimbursement Models to Promote Evidence Generation and Innovation for Genomic Tests. Available from: www.genome.gov/27552210 [Last accessed 24 October 2012]
30. Mosley JD, Keri RA. Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists. Bio Med Cent Genomics 2008;1:11
31. Starmans MH, Krishnapuram B, Steck H, et al. Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer 2008;99(11):1884-90
32. Wistuba II, Behrens C, Lombardi F, et al. Validation of a proliferation-based expression signature as prognostic marker in early stage lung adenocarcinoma. Clin Cancer Res 2013;19(22):6261-71
33. Bueno R, Hughes E, Wagner S, et al. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma. J Thorac Oncol 2015;10(1):67-73
34. Carr SR, Schuchert MJ, Pennathur A, et al. Impact of tumor size on outcomes after anatomic lung resection for stage IA nonsmall cell lung cancer based on the current staging system. J Thorac Cardiovasc Surg 2012;143(2):390-7
35. Bueno R. The 15th world conference on lung cancer. Validation of a 46-gene expression signature in early-stage non-small-cell lung cancer. Lecture conducted from Sydney; Australia: 2013
36. Myriad Genetics, Inc. Myriad myPlanTM lung cancer test launched to leading oncologists test accurately identifies which patients may need post-surgical chemotherapy. Available from: http:// investor.myriad.com/releasedetail.cfm? releaseid=801093 [Last accessed 29 October 2013]
37. Myriad Genetics, Inc. myPlanTM Specimen Instructions. Available from: https://s3. amazonaws.com/myriad-web/myriadpro. com/publications/ 116262-MyPlanInstruc-proof.pdf [Last accessed 14 August 2014]
38. Genome web. MDx/CDx Focus: myriad launches myPlan lung cancer test; NY DOH grants permit for pathway fit; and More. Available from: www.genomeweb. com/clinical-genomics/mdxcdx-focusmyriad- launches-myplan-lung-cancer-test-nydoh- grants-permit-pathwa [Last accessed 30 October 2013]
39. Tang H, Xiao G, Behrens C, et al. A 12-gene set predicts survival benefits from adjuvant chemotherapy in non-small cell lung cancer patients. Clin Cancer Res 2013; 19(6):1577-86
40. Life Technologies. PervenioTM Lung Cancer RS Specimen Requirements. Available from: www.lifelabdx.com/ documents/Pervenio%20Lung%20TRF.pdf [Last accessed 15 August 2014]
41. Adjuvant Chemotherapy in Patients With High Risk Stage I Non-squamous Non-Small Cell Lung Cancer. Available from: https://clinicaltrials.gov/ct2/show/ NCT01817192